Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Retatrutide Injection Sites: Where to Inject and How to Rotate
educationRetatrutide (LY3437943) is injected subcutaneously once weekly into one of the three sites used in Lilly's injection-site study (NCT05959096): abdomen, thigh, or upper arm. It has no FDA-approved label, so this guide follows that study's sites and general injection technique: each site, how to rotate with every dose, site prep, and which local reactions to watch for.
How to Inject Retatrutide: Step-by-Step Technique Guide
articleA step-by-step guide to the retatrutide injection technique, from drawing your dose to sharps disposal. Covers vial-and-syringe and pen formats, needle angle, the pinch, and site rotation, based on the published trial literature and standard subcutaneous injection practice.